Discovering new drugs has never been easy and some potential drug targets have historically been viewed as too challenging and thus off limits for prosecution. In a new SLAS Discovery review, authors John S. Lazo et al. of the University of Virginia reflect on the nature of protein tyrosine phosphatases and explores reasons why these enzymes have been eschewed by drug hunters, and how the landscape is beginning to change.